Abstract We determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the oral vascular endothelial growth factor receptor (VEGFR) inhibitor, sunitinib, when administered with irinotecan among recurrent malignant glioma (MG) patients. For each 42-day cycle, sunitinib was administered once a day for four consecutive weeks followed by a 2 week rest. Irinotecan was administered intravenously every other week. Each agent was alternatively escalated among cohorts of 3-6 patients enrolled at each dose level. Patients on CYP3A-inducing anti-epileptic drugs were not eligible. Twenty-five patients with recurrent MG were enrolled, including 15 (60%) with glioblastoma (GBM) and 10 (40%) with grade 3 MG. Five patients progressed previously on bevacizumab and two had received prior VEGFR tyrosine kinase inhibitor therapy. The MTD was 50 mg of sunitinib combined with 75 mg/m 2 of irinotecan. DLT were primarily hematologic and included grade 4 neutropenia in 3 patients and one patient with grade 4 thrombocytopenia. Non-hematologic DLT included grade 3 mucositis (n = 1) and grade 3 dehydration (n = 1). Progression-free survival (PFS)-6 was 24% and only one patient achieved a radiographic response. The combination of sunitinib and irinotecan was associated with moderate toxicity and limited anti-tumor activity. Further studies with this regimen using the dosing schedules evaluated in this study are not warranted.
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Introduction
The outcome for patients with malignant glioma (MG) remains poor. Nearly all patients recur after standard multimodality therapy that includes maximum safe resection, radiotherapy and temozolomide-based chemotherapy. Median overall survival (OS) for glioblastoma (GBM), the most common type of MG, is only 14.6 months [1] . A contributing factor to overall poor outcome is ineffective therapies for recurrent patients [2] [3] [4] .
MGs are highly angiogenic tumors, and vascular endothelial growth factor (VEGF) is the principal angiogenic growth factor [5, 6] . Targeting VEGF in preclinical orthotopic xenograft GBM models has demonstrated anti-tumor activity [7, 8] . Recent clinical studies have confirmed that VEGF inhibiting therapies have anti-tumor benefit for recurrent GBM patients. Specifically, bevacizumab, a humanized monoclonal antibody against VEGF, was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for recurrent GBM patients based on radiographic responses observed in a single-arm phase II study of bevacizumab monotherapy [9] and a phase II study that randomized patients to either single-agent bevacizumab or bevacizumab with irinotecan [10] .
A second strategy to target angiogenesis for MG patients is inhibition of VEGF receptor (VEGFR) signaling using specific and potent VEGFR tyrosine kinase inhibitors. Sunitinib (Sutent; SU11248; Pfizer, Inc., New York, NY) is an orally-bioavailable pan-VEGFR inhibitor that also inhibits other biologically relevant growth factors in GBM including platelet-derived growth factor receptors (PDGFRa and PDGFRb) and stem cell growth factor receptor (KIT). Sunitinib, which also inhibits ms-like tyrosine kinase 3 (FLT-3), glial cell line-derived neurotrophic factor receptor (RET) and colony stimulating factor-1 receptor (CSF1-R), is currently FDA-approved for renal cell carcinoma and gastrointestinal stromal tumors [11] .
At the time this study was designed, our group had just reported highly encouraging evidence of anti-tumor activity with bevacizumab plus irinotecan (Camptosar; CPT-11), a topoisomerase-1 inhibitor, among heavily pretreated, recurrent MG patients [12, 13] . Studies of singleagent bevacizumab had not been reported. We hypothesized that sunitinib with irinotecan may also have anti-tumor activity and designed this phase I study to evaluate the safety of this combination and determine its maximum tolerated dose (MTD) as well as dose-limiting toxicity (DLT) among recurrent MG patients.
Materials and methods

Protocol objectives
The primary objective of this study was to define the MTD and DLT of sunitinib when administered daily with irinotecan among adults with recurrent MG. Secondary objectives included: to define other toxicities associated with the regimen; and to document antitumor activity. ULN) ; have recovered from all expected toxicity related to previous therapy; and provide written informed consent. In addition, patients were required to be at least 2 weeks from prior surgical resection (1 week for stereotactic biopsy), and 4 weeks from either radiotherapy or chemotherapy (6 weeks for nitrosoureas).
Exclusion criteria were: prior sunitinib therapy; progressive disease (PD) or grade C3 toxicity to prior irinotecan therapy; concurrent administration of warfarin or CYP3A enzyme-inducing anti-epileptic drugs (EIAEDs; phenytoin, phenobarbital, carbamazepine, oxcarbazepine, or primidone); grade [1 intratumoral hemorrhage on baseline imaging; homozygosity for UGT1A1; pregnancy or nursing; significant concurrent medical illness; or prior malignancy requiring active intervention. There was no restriction for eligibility based on number of prior episodes or PD, degree of prior treatment or prior bevacizumab therapy.
Treatment design
Sunitinb and irinotecan were provided by Pfizer, Inc. (New York, New York). Sunitinib was taken orally once a day without regard to food for 4 weeks followed by a 2 week rest for each 42-day treatment cycle. Patients and caregivers were carefully taught how to administer sunitinib and were asked to complete a daily dose administration diary.
Irinotecan was administered intravenously over 90 min on days 1, 15 and 29 of each 42 day cycle. Prior studies confirmed that the metabolism of irinotecan is significantly increased by concurrent use of CYP3A-inducing anti-epileptic drugs (EIAEDs) such as phenytoin, carbamazepine, phenobarbital, oxcarbazepine and primidone [14, 15] . Due to this pharmacokinetic interaction, combined with a decreasing frequency of EIAED use among MG patients in general, patients who required EIAEDs were excluded from the current study.
The starting dose of sunitinib was 25 mg once a day for 4 weeks followed by a 2 week rest and the starting dose of irinotecan was 75 mg/m 2 . Based on the dose escalation design (Table 1) , each agent was escalated in a staggered manner in successive patient cohorts. The fifth and final planned dose level included the standard, full dose of each agent. Cohorts of 3-6 patients were treated per dose level until DLT was observed.
Dose escalation and statistical considerations
Three patients were accrued in successive cohorts at each dose level as long as DLT did not occur. If one instance of DLT was observed among the initial three evaluable patients, an additional three patients were treated at that dose level. Dose escalation then continued as long as no DLT occurred in these additional patients. If two instances of DLT were observed at a dose level, the MTD was surpassed, and a total of six patients were treated at the previous level to assure its tolerability. MTD was defined as the highest dose causing DLT during cycle 1 in no more than one of six patients.
Non-hematologic DLT included Cgrade 3 attributable toxicities, except for alopecia, nausea, vomiting or diarrhea that responded to standard medical therapy. Hematologic DLT included either grade 4 neutropenia or grade 3 thrombocytopenia. Any toxicity resulting in a [14-day delay to re-treat was also considered DLT.
Time to progression (TTP) and OS were measured from treatment initiation and analyzed by the Kaplan-Meier method including 95% confidence intervals (CIs).
Toxicity evaluation
Toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0. Patients were evaluated by physical examination before each cycle. In addition, blood pressure was measured every other week. A complete blood count with differential was obtained weekly, and serum electrolytes, BUN/creatinine and liver function tests as well as urinalysis were obtained before every cycle. A beta human chorionic gonadotropin test was performed prior to the first cycle in women with reproductive potential. Patients who experienced DLT or unacceptable toxicity were followed weekly until toxicity resolved.
Response evaluation
Response was evaluated by neurologic examination and contrast-enhanced MRI prior to the start of every treatment cycle and was graded using modified Macdonald criteria [16] . Radiologic assessment in neuro-oncology (RANO) criteria [17] were not used because they were not defined prior to the execution of this study.
Dose modification and retreatment criteria
Re-treatment required adequate hematologic and biochemical parameters (defined in eligibility criteria) and resolution of any treatment-related grade C3 toxicity to grade B1. Dose reduction of both sunitinib and irinotecan by one dose level were instituted for DLTs during study drug administration. The dose of irinotecan was planned to be decreased to 50 mg/m 2 for patients who experienced DLT in dose level one.
Study therapy was discontinued for unacceptable toxicity despite appropriate dose modification, PD or withdrawal of consent.
Pharmacokinetic analysis
The study protocol included an optional dose expansion of six patients to determine pharmacokinetics of sunitinib and irinotecan at the MTD. However, due to limited evidence of anti-tumor activity observed during the performance of the dose escalation portion of this trial, the sponsor and study investigators determined that further investigation of this study regimen was unlikely to be considered. Hence, the dose expansion portion of this protocol to evaluate pharmacokinetics of the study agents was electively not pursued, and therefore there are no results of the pharmacokinetic of the study regimen.
Results
Patient characteristics
Twenty-five patients with recurrent MG were enrolled at Duke University Medical Center between April, 2008 and April, 2010 ( Table 2 ). Fifteen patients had GBM (60%), 8 had anaplastic astrocytomas (AA) (32%) and 2 patients had anaplastic oligodendroglioma (8%). None of the patients had debulking surgery prior to study enrollment. All patients had PD after at least radiotherapy and chemotherapy including temozolomide. Fourteen patients (56%) enrolled after their first episode of PD, while 11 enrolled after 2 or more progressions. The median time from original diagnosis to study enrollment was 18.8 months (range, 5.0-1274.8 months). Five patients had received prior bevacizumab and two patients had been treated with an alternative VEGFR tyrosine kinase inhibitor (vandetanib). Four patients (16%) had received prior irinotecan. As of April 1, 2011, 9 patients (36%) remain alive and 16 have died of progressive tumor. All patients have discontinued study therapy.
DLT and non-DLT
Fifty-seven courses of sunitinib and irinotecan were administered. Table 3 summarizes the frequency of attributable grade C2 adverse events. Neutropenia was the most common grade C2 adverse event and affected 13 patients (52%), while fatigue was the next most common toxicity and affected 9 patients (36%), but was grade 2 in seven. The frequency of grade C3 hematologic adverse events was unexpected and affected 12 patients (48%) including eight patients with neutropenia, three patients with thrombocytopenia and one patient with anemia. Grade C2 electrolyte abnormalities were also fairly common and affected 10 patients (40%), and included hypophosphatemia (n = 4), hypocalcemia (n = 2) and hypokalemia (n = 2). Grade C3 amylase/lipase occurred in two patients. Both patients were symptomatic but the event reversed with appropriate medical management. Table 4 summarizes DLTs by dose level. Three out of four DLTs were hematologic. One out of six patients experienced DLT at both dose levels two and three, respectively, while two out of six patients treated at dose level four experienced DLT. These results confirmed the MTD of sunitinib to be 50 mg daily for four consecutive weeks when combined with irinotecan administered at 75 mg/m 2 every other week.
Outcome
The median follow-up for all patients was 100.1 weeks (95% CI, 58.1-126.7 weeks). The 6-month progressionfree survival (PFS) rate, median PFS and median OS for all patients were 24% (95% CI: 9.8, 41.7), 6.9 weeks (95% CI: 5.7, 17.7 weeks), and 53.1 weeks (95% CI: 30.3, 87.9 weeks). All patients were evaluable for response. One patient (4%) achieved a radiographic partial response (PR) and 9 (36%) patients achieved stable disease (SD). PD was noted at initial evaluation in 15 patients (60%).
Discussion
This study was designed just after the regimen of bevacizumab and irinotecan was reported to be associated with AA anaplastic astrocytoma, AO anaplastic oligodendroglioma, GBM glioblastoma, KPS Karnofsky performance status, TKI tyrosine kinase inhibitor, VEGFR vascular endothelial growth factor receptor a radiographic response rate of approximately 57% and PFS-6 of 46% among recurrent GBM patients [13] . These results contrasted strikingly with those of recent metaanalyses of salvage therapies from the pre-bevacizumab era that reported radiographic response and PFS-6 rates less than 10%, respectively [2] [3] [4] . We hypothesized that sunitinib and irinotecan may have clinical activity similar to that initially reported for bevacizumab and irinotecan among recurrent MG patients and designed the current study to determine the MTD and DLT of this regimen in this patient population. Sunitinib is an attractive therapeutic option for GBM because it targets several biologically relevant tyrosine kinases. First, it is a pan-VEGFR inhibitor. Second, it blocks PDGFRa and PDGFR-b, which are overexpressed in a subset of GBM and linked with gliomagenesis in neural stem cell models [18] [19] [20] [21] . PDGFRs are also important mediators of pericyte activation and stabilization of tumor vasculature [22, 23] . Third, sunitinib also inhibits c-KIT, a growth factor receptor that has been shown to be overexpressed and amplified in a subset of GBM tumors [24, 25] .
Sunitinib is currently FDA approved for renal cell carcinoma as well as gastrointestinal stromal tumors [11] and has shown encouraging activity in several other solid tumors [26] [27] [28] [29] . Effective penetration into the CNS has been inferred by reports of brain metastases undergoing regression following sunitinib therapy [30] [31] [32] .
Preclinical studies suggest that sunitinib has activity against MG. In an organotypic MG brain slice model, sunitinib therapy enhanced apoptosis and decreased tumor cell proliferation, angiogenesis and invasion, while treatment of U87MG intracranial xenografts resulted in growth delay and diminished microvessel density [33] . Chahal et al. [34] demonstrated that sunitinib decreased proliferation and survival of MGMT-transfected U87MG cells treated with radiotherapy alone, temozolomide alone or the combination, but did not affect U87MG MGMT negative cells. Sunitinib has also been shown to augment the cytotoxicity of chemotherapy in a flank xenograft GBM model [35] . Finally, sunitinib therapy can enhance the intratumoral delivery of temozolomide in intracranial MG models, consistent with vascular normalization [36] .
Only one clinical study of sunitinib among recurrent MG patients has been reported to date [37] . In a series of 21 patients, single-agent sunitinib administered at 37.5 mg continuous, once daily oral dosing, was well tolerated but failed to achieve any objective radiographic responses and was associated with a median PFS of only 1.6 months.
In the current study, we evaluated sunitinib administered at the conventional once daily schedule for 4 weeks followed by a 2 week rest, in combination with irinotecan administered every other week. Although the MTD included sunitinib at 50 mg/day, which is the established singleagent dose, irinotecan was only able to be escalated to 75 mg/m 2 . The regimen was associated with an increased rate of grade C3 hematologic toxicity than reported with single-agent Sunitinib [37] , which included neutropenia or thrombocytopenia in 11 patients (40%). Grade 2 or 3 electrolyte deficiencies, including hypocalcemia, hypokalemia and hypophosphatemia were also common and occurred in 8 patients (32%). The etiology of these adverse events is unclear but may be related to the multi-targeted activity of sunitinib or to its combination with irinotecan. Although pharmacokinetic evaluations were not performed, detrimental interactions with increased accumulation of metabolites may have contributed to the observed toxicity given the shared pathways of metabolism of sunitinib and irinotecan.
Although this was a phase I study, and therefore not designed to evaluate efficacy, we noted that the regimen of sunitinib and irinotecan was associated with limited evidence of anti-tumor activity. As described above, singleagent sunitinib was also associated with minimal antitumor activity among recurrent GBM patients [37] . Other VEGFR TKIs have also noted disappointing results among recurrent MG patients [38] [39] [40] , although the reason underlying their apparent inferior anti-tumor activity relative to bevacizumab remains unclear. A factor that may have contributed to the low level of anti-tumor activity noted in this study was that 28% of the enrolled patients had received prior VEGF/VEGFR-directed therapy.
In conclusion, we established the MTD of sunitinib and irinotecan in this phase I, dose escalation study. The regimen was associated with moderate toxicity and limited anti-tumor activity. An elective dose expansion at the MTD to evaluated pharmacokinetics and potential correlative biomarkers of response was not pursued due to toxicity and limited anti-tumor activity observed during the dose escalation portion of this study. Further evaluation of this regimen utilizing this dose schedule among MG patients is not warranted.
